Resumes
Resumes
Gilles Goetz Phones & Addresses
-
11 Whittlesey Ct, Niantic, CT 06357 (860) 501-2635
-
Chesterfield, MO
-
2331 Seven Pines Dr, Saint Louis, MO 63146 (314) 576-3545
-
Honolulu, HI
-
11 Whittlesey Ct, Niantic, CT 06357
Education
Degree:
Associate degree or higher
Publications
Us Patents
Protease Inhibitors Of The Coagulation Cascade Isolated From Dysidea Sponges
View pageUS Patent:
6939565, Sep 6, 2005
Filed:
Jan 16, 2004
Appl. No.:
10/759667
Inventors:
Gilles H. Goetz - Chesterfield MO, US
George G. Harrigan - St. Louis MO, US
John J. Likos - St. Louis MO, US
Thomas P. Kasten - O'Fallon IL, US
George G. Harrigan - St. Louis MO, US
John J. Likos - St. Louis MO, US
Thomas P. Kasten - O'Fallon IL, US
Assignee:
Pharmacia Corporation - St. Louis MO
International Classification:
A61K035/56
C07D209/14
C07D209/14
US Classification:
424520, 548468, 424537
Abstract:
The present invention is directed toward a composition comprising a compound isolated from species sponges that is capable of inhibiting serine proteases of the coagulation cascade. In particular, this composition inhibits the TF/VIIa complex of the coagulation cascade. The invention is also directed toward methods employing this composition as a part of anticoagulant therapy.
Protease Inhibitors Of The Coagulation Cascade Isolated From Dysidea Sponges
View pageUS Patent:
20030158248, Aug 21, 2003
Filed:
Dec 2, 2002
Appl. No.:
10/307803
Inventors:
Gilles Goetz - Chesterfield MO, US
George Harrigan - St. Louis MO, US
John Likos - St. Louis MO, US
Thomas Kasten - O' Fallon IL, US
George Harrigan - St. Louis MO, US
John Likos - St. Louis MO, US
Thomas Kasten - O' Fallon IL, US
Assignee:
Pharmacia Corporation
International Classification:
A61K038/04
C 07D 4 3/02
A61K031/405
C 07D 4 3/02
A61K031/405
US Classification:
514/414000, 514/019000, 548/465000
Abstract:
The present invention is directed toward a composition comprising a compound isolated from Dysidea species sponges that is capable of inhibiting serine proteases of the coagulation cascade. In particular, this composition inhibits the TF/VIIa complex of the coagulation cascade. The invention is also directed toward methods employing this composition as a part of anticoagulant therapy.